Answers are grounded in this paper and cite their sources.
Study synthesizes novel β-lactam derivatives, enhancing antibacterial activity, indicating new treatment options.
<ns5:p> Background Antibacterial agents containing β-lactam derivatives have been widely used in medicine because of their broad-spectrum effectiveness against various infectious diseases. β-Lactam antibiotics remain one of the most important classes of antibacterial agents, and the development of new β-lactam derivatives continues to be essential for overcoming microbial resistance. Therefore, the discovery of novel β-lactam compounds remains an important area in medicinal chemistry for the development of improved antibacterial agents. Objective The present study aimed to synthesize new β-lactam derivatives derived from sulfapyridine Schiff bases and to evaluate their biological activity using laboratory investigations and molecular docking analysis. Methods Sulfapyridine-derived Schiff bases were prepared through condensation reactions with different aromatic aldehydes and used as key intermediates for the synthesis of β-lactam derivatives. The structures of the synthesized compounds were confirmed using FT-IR, <ns5:sup>1</ns5:sup> H-NMR, and <ns5:sup>13</ns5:sup> C-NMR spectroscopic techniques. Two series of β-lactam derivatives were synthesized. The first series [A5–A8] was obtained through the reaction of Schiff bases [A1–A4] with chloroacetyl chloride in the presence of triethylamine. The second series [A9–A12] was synthesized through cycloaddition reactions between the prepared Schiff bases and diclofenac acid in the presence of ρ-toluenesulfonyl chloride and trimethylamine. The synthesized compounds were biologically evaluated, and molecular docking studies were carried out against biologically relevant bacterial targets, including <ns5:italic>Escherichia coli</ns5:italic> (PDB ID: 2EG7) and <ns5:italic>Staphylococcus aureus</ns5:italic> (PDB ID: 2W9S). Results Molecular docking studies were performed to evaluate the antibacterial activity of compounds A5–A12 against <ns5:italic>Escherichia coli</ns5:italic> and <ns5:italic>Staphylococcus aureus.</ns5:italic> Several synthesized derivatives, particularly A7–A9 and A12, exhibited enhanced antibacterial activity compared with the reference drug. Experimental and theoretical findings suggested that β-lactam-based compounds may serve as promising scaffolds for the development of new antibacterial agents. Compared with amoxicillin (−7.5 kcal/mol), compounds A10 and A11 demonstrated lower binding energies (−9.0 and − 8.4 kcal/mol, respectively), indicating strong interactions with bacterial target proteins. Conclusion Molecular docking studies supported the experimental antibacterial findings and provided insight into possible ligand–protein interactions, confirming the biological potential of the synthesized β-lactam derivatives. These findings support the continued investigation of β-lactam scaffolds as promising candidates for future antibacterial drug development. </ns5:p>
No takes yet. Share an insight, caveat, or question.
Yasein et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: